[go: up one dir, main page]

WO2003039482A3 - Polymorphs of fexofenadine base - Google Patents

Polymorphs of fexofenadine base Download PDF

Info

Publication number
WO2003039482A3
WO2003039482A3 PCT/US2002/035996 US0235996W WO03039482A3 WO 2003039482 A3 WO2003039482 A3 WO 2003039482A3 US 0235996 W US0235996 W US 0235996W WO 03039482 A3 WO03039482 A3 WO 03039482A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphs
fexofenadine base
forms
present
fexofenadine
Prior art date
Application number
PCT/US2002/035996
Other languages
French (fr)
Other versions
WO2003039482A8 (en
WO2003039482A2 (en
Inventor
Barnaba Krochmal
Dov Diller
Ben-Zion Dolitzky
Judith Aronhime
Shlomit Wizel
Original Assignee
Teva Pharma
Barnaba Krochmal
Dov Diller
Ben-Zion Dolitzky
Judith Aronhime
Shlomit Wizel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/118,807 external-priority patent/US20020177608A1/en
Priority claimed from US10/133,460 external-priority patent/US20030021849A1/en
Application filed by Teva Pharma, Barnaba Krochmal, Dov Diller, Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel filed Critical Teva Pharma
Priority to JP2003541774A priority Critical patent/JP2005537218A/en
Priority to IL16181602A priority patent/IL161816A0/en
Priority to EP02792238A priority patent/EP1453509A2/en
Priority to CA002465913A priority patent/CA2465913A1/en
Priority to AU2002357701A priority patent/AU2002357701A1/en
Publication of WO2003039482A2 publication Critical patent/WO2003039482A2/en
Publication of WO2003039482A3 publication Critical patent/WO2003039482A3/en
Publication of WO2003039482A8 publication Critical patent/WO2003039482A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel crystal forms of fexofenadine base and processes for their preparation. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.
PCT/US2002/035996 2001-11-08 2002-11-08 Polymorphs of fexofenadine base WO2003039482A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003541774A JP2005537218A (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
IL16181602A IL161816A0 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
EP02792238A EP1453509A2 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
CA002465913A CA2465913A1 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
AU2002357701A AU2002357701A1 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US33693001P 2001-11-08 2001-11-08
US60/336,930 2001-11-08
US33904101P 2001-12-07 2001-12-07
US60/339,041 2001-12-07
US34411401P 2001-12-28 2001-12-28
US60/344,114 2001-12-28
US36178002P 2002-03-04 2002-03-04
US60/361,780 2002-03-04
US36348202P 2002-03-11 2002-03-11
US60/363,482 2002-03-11
US10/118,807 US20020177608A1 (en) 2001-04-09 2002-04-08 Polymorphs of fexofenadine hydrochloride
US10/118,807 2002-04-08
US10/133,460 US20030021849A1 (en) 2001-04-09 2002-04-26 Polymorphs of fexofenadine hydrochloride
US10/133,460 2002-04-26
US38767002P 2002-06-10 2002-06-10
US39019802P 2002-06-19 2002-06-19
US60/390,198 2002-06-19
US40376502P 2002-08-15 2002-08-15
US60/403,765 2002-08-15
US40621402P 2002-08-27 2002-08-27
US60/406,214 2002-08-27
US60/387,670 2002-10-06

Publications (3)

Publication Number Publication Date
WO2003039482A2 WO2003039482A2 (en) 2003-05-15
WO2003039482A3 true WO2003039482A3 (en) 2003-11-20
WO2003039482A8 WO2003039482A8 (en) 2005-01-06

Family

ID=29424979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035996 WO2003039482A2 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base

Country Status (4)

Country Link
EP (1) EP1453509A2 (en)
AU (1) AU2002357701A1 (en)
CA (1) CA2465913A1 (en)
WO (1) WO2003039482A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ITMI20041143A1 (en) * 2004-06-08 2004-09-08 Dipharma Spa FEXOFENADINA POLYMORPHS AND PROCEDURE FOR THEIR PREPARATION
ITMI20041568A1 (en) * 2004-07-30 2004-10-30 Dipharma Spa "BASE FEXOFENADINA POLYMORPHS"
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
MX383715B (en) 2013-11-15 2025-03-14 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5589487A (en) * 1993-06-24 1996-12-31 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5589487A (en) * 1993-06-24 1996-12-31 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"X-ray diffraction", NATIONAL FORMULARY, 1995, pages 1843 - 1844, XP002963646 *

Also Published As

Publication number Publication date
WO2003039482A8 (en) 2005-01-06
AU2002357701A1 (en) 2003-05-19
WO2003039482A2 (en) 2003-05-15
EP1453509A2 (en) 2004-09-08
CA2465913A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
EP1887007A3 (en) Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
WO2003028641A3 (en) Mch receptor antagonists
CA2466724A1 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
PL370381A1 (en) Substituted piperazines as modulators of the melanocortin receptor
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
SE0101675D0 (en) Novel composition
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
WO2005033099A3 (en) Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2006020959A3 (en) Substituted benzofused heterocycles
WO2005061467A3 (en) Piperazine derivatives as bradykinin antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2002080857A3 (en) Polymorphs of fexofenadine hydrochloride
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2004050618A8 (en) Crystalline form f of atorvastatin hemi-calcium salt
WO2005075467A3 (en) Crystalline forms of zolmitriptan
WO2003039482A8 (en) Polymorphs of fexofenadine base
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2004037844A8 (en) Crystalline 17beta-hydroxy-7alpha- (5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma-lactone
WO2002044128A3 (en) Salicylate analogs as interleukin-4 antagonists
HUP0401895A2 (en) N-formyl derivatives of paroxetine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2465913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 161816

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003541774

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002792238

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792238

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792238

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 20/2003 UNDER (30) REPLACE "60/387, 670, 06 OCTOBER 2002 (06.10.2002), US" BY "60/387, 670, 10 JUNE 2002 (10.06.2002), US"